Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

LOS ANGELES, Sept. 07, 2023 -- Immix Biopharma, Inc. a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella...

Related Keywords

California ,United States ,Mike Moyer ,Gabriel Morris ,Los Angeles ,Ilya Rachman ,Immix Biopharma Inc ,Nexcella Inc ,Company Conference ,Exchange Commission ,Nasdaq ,Company Contact ,Chief Executive Officer ,Chief Financial Officer ,Immix Biopharma ,Tissue Specific Therapeutics ,Tissue Specific Therapeutic ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Risk Factor ,Annual Report ,Markets ,